Biologic and Cell Solutions
Achieve Success with Biologic Drugs and Cell Therapies
As the healthcare system moves away from treatments that focus on the symptoms of a disease and towards curing the disorder, new technologies are necessary to achieve success. Historically the pharmaceutical industry utilized small molecules and chemicals as active ingredients in drugs, but cures require more complex entities such as cell therapies, peptides and antibodies.
Thus, novel methods to deliver these therapies are needed. Without a targeted delivery system, the chances of biological drugs or cell therapies succeeding in clinical trials is decreased.
Core-Shell Spherification® (CSS) is a platform delivery technology that coats (encapsulates) biological therapies including cells, cell clusters, peptides, scaffolds and antibodies in a hydrogel. CSS is completely unique because it can utilize hydrogels that were once thought to be unavailable for encapsulation such as hyaluronic acid and PEG-based hydrogels. These hydrogels are already successfully used in areas including wound healing, dermal fillers, and cosmetic applications.
For the first time, a delivery system is now available for the newest classes of therapies that biotech companies are developing. CSS maintains and slowly releases the biological in a target location. Tunable control over formulations allows control of factors such as microbead size, release rates, and loading densities, providing a wealth of opportunity to create successful cell-based therapeutics.
Delivering Efficient Cell Therapies That Change Lives
Discover a whole new modality for the delivery of cell therapies. We have the first and only customizable platform for targeting cell therapies to increase their potency.
What We Do For Humans
By using better encapsulants, new opportunities unfold to treat specific diseases. CSS® enables cell therapies to function where they’ve never functioned before.
Ongoing or Completed U.S. Clinical Trials Using Stem Cells
as listed in the National Institutes of Health/FDA-approved database. (accessed Dec 2021)
…but few have made their way to the patient. The majority fail in Phase I and I/II. (Trounson A & McDonald C 2015; Stem Cell Therapies in Clinical Trials: Progress and Challenges; Cell Stem Cell 17, July 2015)
60%+ of FDA Approved Cell Therapies Focus on Blood Disorders
Many others focus on topical or superficial uses such as treating burns, wounds or for cosmetic applications. While an IV injection of cells may be successful to target blood diseases, obtaining a sufficient dosage at a targeted organ or tissue is still a major challenge. (US Food & Drug Administration, Aproved Celular and Gene Therapy Products; accessed Dec 2021)
We help our partners solve the following…